When Hope Overrides Evidence: The FDA’s Rare Disease Dilemma and the Future of Drug Approval

The FDA’s controversial approval of Forzinity for Barth syndrome, despite scant clinical evidence and strong internal objections, highlights a historic turning point: When patient advocacy and political pressure outweigh scientific consensus, the entire U.S. drug approval landscape—and the price patients and the healthcare system pay—may be fundamentally transformed.

The Core Issue: Scientific Evidence vs. Patient Demand

On September 19, 2025, the U.S. Food and Drug Administration (FDA) approved Forzinity (elamipretide) for Barth syndrome—a life-threatening, ultra-rare genetic disorder affecting about 150 mostly male patients across the United States. This was the first-ever approved treatment for Barth syndrome, hailed as a victory by affected families and advocates. But beneath the celebration, FDA documents reveal an uncomfortable reality: the agency’s own scientists found that Forzinity was no more effective than a placebo in its pivotal trial and recommended against its approval.^Reuters

What drove the final decision? A confluence of factors: desperate patient need, intense advocacy, and political momentum favoring approvals for treatments of rare diseases, even if they come at a staggering financial cost—up to $800,000 per year per patient.

Historical Precedents: When the FDA Bows to Pressure

This is not the first time the FDA has overruled its own scientific panel due to public and political pressure. In 2016, the agency controversially approved eteplirsen (Exondys 51) for Duchenne muscular dystrophy over reviewer objections and limited efficacy evidence, swayed largely by emotional testimony and advocacy from affected families.^{STAT News}

In the 1980s, HIV/AIDS activists effectively reshaped drug approval policy by demanding accelerated access to medications, leading to the 1992 Accelerated Approval pathway.^{FDA Accelerated Approval History}
Pressure from advocacy groups has repeatedly forced the agency to weigh uncertainty of evidence against the certain suffering of patients with no alternative options.

Each time, the dilemma is the same: Should regulatory bodies hold the line on scientific standards, or bend in the face of personal stories and grassroots activism? The FDA’s action on Forzinity echoes a longstanding trend—but at a much steeper price, and with staggering implications for the future.

Josanne Archibald carries her son Josiah Archibald, who has Barth syndrome, at Dorney Park in Allentown, Pennsylvania, U.S., September 7, 2025. Josanne Archibald/Handout via REUTERS — Patient stories like Josiah Archibald’s were central in advocacy for approval, illustrating the real-world consequences for ultra-rare disease families. **Image: Reuters**

Systemic Implications: Is the Bar Lower for Rare Diseases?

The approval of Forzinity under expedited review, following new policy changes that allow rare disease drugs to move forward based on a single “strong” study and supporting evidence, opens a new chapter of flexibility in the FDA’s standards. While understandable for devastating, untreatable illnesses, this approach has key systemic risks:

Scientific Rigor vs. Compassionate Approval: Eroding the gold standard for evidence risks harmless but ineffective—or even harmful—treatments reaching desperate patients.^{JAMA: FDA Approvals for Rare Diseases}
New Precedent for Advocacy: Each “exception” strengthens the de facto power of patient advocacy to influence regulatory decisions. This trend can lead to a patchwork of evidentiary standards in drug approval, with ultra-rare conditions judged by a fundamentally different yardstick than more common diseases.
Healthcare Economics: Forzinity’s near $800,000 price tag is not an outlier; many orphan drugs are priced in the six- to seven-figure range, with insurers forced to foot the bill due to lack of competition.^{Duke Health Policy on Orphan Drug Prices}

Julianna Archibald, 8, sits with her siblings Josiah Archibald, 1, Mason Archibald, 10, and Elijah Phillips, 19, all three of whom have Barth syndrome, at the Great Wolf Lodge in Scotrun, Pennsylvania, U.S., April 19, 2025. Josanne Archibald/Handout via REUTERS — Barth syndrome’s small patient population underscores the unique challenges and ethical dilemmas in ultra-rare drug approval. **Image: Reuters**

Who Wins? Who Loses? Second- and Third-Order Effects

Patients and Families: For those facing previously untreatable conditions, any shot at relief or survival is profoundly significant. Yet, families must navigate drug costs, insurance battles, and the uncertainty of real-world effectiveness.
Biotech Industry: High prices can incentivize investment in rare disease drug R&D, but also open the door for “me-too” drugs and potentially lower regulatory hurdles to recoup development costs.
The Healthcare System: Insurers and public payers—ultimately, American patients and taxpayers—shoulder the burden of high prices for drugs whose effectiveness is often unclear. This dynamic is already inflating costs across the rare disease landscape.^{Health Affairs: Orphan Drug Spending}
FDA and Policy Integrity: Every precedent that privileges compassion over clinical proof makes it harder to maintain consistent standards—and easier for future drugs of dubious value to reach the market.

Josiah Archibald, who has Barth syndrome, sits in a crib at his home in Dumont, New Jersey, April 20, 2025. Josanne Archibald/Handout via REUTERS — Ultra-rare diseases like Barth syndrome often impact entire families—and their stories resonate deeply in the political and regulatory process. **Image: Reuters**

Patient advocacy for those with rare diseases has been a moral force for decades, resulting in lifesaving therapies and the landmark Orphan Drug Act of 1983.^Congress.gov But with each leap of faith the FDA takes on behalf of ultra-rare disease patients, the agency is forging a new social contract: one prioritizing access and hope, sometimes at the expense of conclusive scientific proof.

This raises urgent questions for the future:

What safeguards can ensure that new drugs work as promised, especially when initial studies are inconclusive?
Will a patchwork of evidentiary standards take hold, and at what cost to science and society?
How should society balance the needs of the few against the imperative of fair, evidence-based policy for all?

Looking Ahead: The Path Forward for Patients, Policymakers, and Science

The FDA’s Forzinity decision is more than a headline about a single drug. It’s a bold statement about what the United States values most in its drug approval process: hope, sometimes over certainty. As the agency continues to navigate the tension between scientific rigor and public demand, it will shape the environment for future therapies, the biotech market, and the trust Americans place in science-based regulation.

For ultra-rare diseases, the FDA’s evolving stance on evidence and access is both an opportunity and a risk. The coming years will reveal whether “flexibility” leads to genuine breakthroughs or unleashes a flood of costly and marginally effective treatments—changing the American healthcare landscape for everyone.